Drug Discovery

Inside the Alzheimer's Lab: Interviews With Our Researchers

Posted: Mar. 21, 2014

Over the past few years, our understanding of Alzheimer’s disease has increased immensely. We can now identify three distinct parts of the disease pathology: early-stage Abeta (amyloid) accumulation, mid-stage development of tau tangles, and late-stage inflammation.

Scientists on our Research Consortium are investigating all three of these points of intervention. On March 6, we talked to Drs. Steven Wagner, David Holtzman, and Rudy Tanzi about how their labs are working to stop Alzheimer’s in its early, middle, and late stages.

Francis Collins Addresses Senate on Alzheimer's and Dementia

Posted: Feb. 27, 2014

On Wednesday, February 26, 2014, a U.S. Senate subcommittee heard from several panelists on the state of research, funding and awareness for Alzheimer's disease and related dementias. The first panel was led by Dr. Francis Collins, director of the National Institutes of Health (NIH). In his talk, Dr. Collins describes much of the research being conducted by Cure Alzheimer’s Fund, which is focused on identifying both the causes of Alzheimer’s disease and identifying therapeutic targets for drug discovery to prevent cognitive decline.

Drug Development Strategy: Three Points of Attack

Posted: Jan. 28, 2014

In view of an emerging consensus on how Alzheimer’s disease develops and progresses, the Cure Alzheimer’s Fund Research Consortium aggressively is focusing on three opportunities for possible intervention—at the early stage of the disease, the middle stage and the late stage. This comprehensive strategy addresses the whole picture of how Alzheimer’s disease develops and progresses, and attacks all three points simultaneously.

Desperate For a Cure: The Search for New Alzheimer's Treatments

Posted: Oct. 4, 2013

"Desperate For A Cure: The Search For New Alzheimer's Treatments", a new five-part series by NPR's Sean Corcoran, aired this week on WCAI and will air again next week on WGBH in Boston.

Targretin Fails: High Hopes Dashed for a New Treatment for Alzheimer’s

Posted: May 24, 2013

While many were anxious to accept initial findings showing a drug known as Targretin’s “too good to be true” lab results with Alzheimer’s disease, subsequent attempts to confirm and replicate the original data regarding the ability of Targretin to remove amyloid plaques, the cardinal lesion of the disease, have largely failed. Cure Alzheimer’s Fund Research Consortium members Dr. Sangram Sisodia, professor of neuroscience at the University of Chicago and Dr.

Public/Private Funding of Research on Alzheimer's Disease Guides Drug Discovery

Posted: May 6, 2013

Cure Alzheimer’s Fund and National Institute of Mental Health Join in Awarding Millions for Whole Genome Sequencing

Stem Cells Accelerate Research & Drug Discovery

Posted: Mar. 21, 2013

Washington—Uncovering the cure for Alzheimer’s disease at a rate never before possible and giving individuals a way to better understand their chances of facing Alzheimer’s are the outcomes of new advances in stem cell research from the Cure Alzheimer’s Fund (CAF) Stem Cell Research Consortium that use skin samples to identify potential therapies for the disease.

$5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development

Posted: Oct. 18, 2012

Largest Single Private Investment in Alzheimer’s Whole Genome Sequencing Targets Effective Therapies and Cure: $5.4 Million Awarded for Research to Guide Alzheimer’s Drug Development

Understanding who is most susceptible to Alzheimer’s disease and developing early detection models, effective therapies and possibly a cure, is the goal of the largest single private scientific grant ever invested in Alzheimer’s Whole Genome Sequencing (WGS) focused on families afflicted with the disease.

Eli Lilly Drug Slows Decline in Early-Stage Patients

Posted: Oct. 9, 2012

October 9 -- Eli Lilly announced encouraging results yesterday involving their experimental drug Solanezumab. Solanezumab is an antibody aimed at lowering beta-amyloid levels in the brain. In trials lasting 18 months, patients with mild Alzheimer's symptoms taking Solanezumab showed significantly less cognitive decline -- 34% less -- compared with patients taking the placebo.

Bexarotene, a new wonder drug for Alzheimer’s?

Posted: Feb. 10, 2012

Dr. Gary Landreth and colleagues at Case Western Reserve published a paper online in Science Express yesterday that received much attention because of the rather stunning results it reports in stopping and even reversing “a broad range of Abeta-induced deficits."